Mandate

Vinge advises NatWest Markets in connection with a securitisation of secured SME loans

May 19, 2021 Banking and Finance

Vinge has acted for NatWest Markets N.V. as senior lender in the structuring, documenting and execution of a securitisation of secured loans to small and medium sized enterprises (SMEs) granted by DBT Capital AB and its subsidiary (”DBT”), in cooperation with, amongst others, the management of DBT and DBT’s legal advisor. In connection with the securitisation, DBT entered into an up to SEK 1,000,000,000 financing agreement with NatWest Markets as senior lender.

DBT is a Swedish private lender registered with the Swedish Financial Supervisory Authority and who offers corporate loans and financing to SMEs in Sweden.

The transaction is executed and reported under the EU securitisation regulation (Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017) and is subject to the reporting requirements thereunder.

Vinge’s team consisted primarily of responsible partner Albert Wållgren together with associates Lionardo Ojeda, Paulina Malmberg, Seyran Sahin, Axel Jansson, Elin Samara and Rebecka Målquist.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024